Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains

Faulkner, Nikhil; Ng, Kevin W.; Wu, Mary; Harvey, Ruth; Margaritis, Marios; Paraskevopoulou, Stavroula; Houlihan, Catherine; Hussain, Saira; Greco, Maria; Bolland, William; Warchal, Scott; Heaney, Judith; Rickman, Hannah; Spyer, Moira; Frampton, Daniel; Byott, Matthew; Oliveira, Túlio de; Sigal, Alex; Kjær, Svend; Swanton, Charles; Gandhi, Sonia; Beale, Rupert; Gamblin, Steve; McCauley, John W.; Daniels, Rodney S.; Howell, Michael; Bauer, David L.V.; Nastouli, Eleni; Investigators, Safer; Kassiotis, George

doi:10.1101/2021.03.01.433314

Cited by 23 publications

(28 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once again, additional follow ups will refine our data. Finally, in line with other reports [23], we demonstrate that infection by the G614-containing 20E (EU1) and B.1.1.7 variants elicits cross-neutralizing responses against former viral variants.…”

Section: Discussionsupporting

confidence: 93%

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals

Trinité

Pradenas

Marfil

et al. 2021

Viruses

View full text Add to dashboard Cite

With the spread of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a need to assess the protection conferred by both previous infections and current vaccination. Here we tested the neutralizing activity of infected and/or vaccinated individuals against pseudoviruses expressing the spike of the original SARS-CoV-2 isolate Wuhan-Hu-1 (WH1), the D614G mutant and the B.1.1.7 variant. Our data show that parameters of natural infection (time from infection and nature of the infecting variant) determined cross-neutralization. Uninfected vaccinees showed a small reduction in neutralization against the B.1.1.7 variant compared to both the WH1 strain and the D614G mutant. Interestingly, upon vaccination, previously infected individuals developed more robust neutralizing responses against B.1.1.7, suggesting that vaccines can boost the neutralization breadth conferred by natural infection.

show abstract

Section: Discussionsupporting

confidence: 93%

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals

Trinité

Pradenas

Marfil

et al. 2021

Viruses

View full text Add to dashboard Cite

show abstract

“…Breakthrough infections and the emergence of VoC highlight the limitations of SARS-CoV-2 S specific plasma antibodies alone to recognize and protect against VoC, and work by our group and others, [9,[28][29][30] has shown that serum or plasma antibodies elicited by natural infection are less potent overall against several VoC. However, serologic studies do not capture the antibodies that will be secreted by MBCs when they are stimulated, expand, and differentiate into a new population of antibody secreting cells.…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 specific memory B-cells from individuals with diverse disease severities recognize SARS-CoV-2 variants of concern

Lyski

Brunton

Strnad

et al. 2021

Preprint

View full text Add to dashboard Cite

In this investigation we examined the magnitude, breadth, and durability of SARS-CoV-2 specific antibodies in two distinct B-cell compartments: long-lived plasma cell-derived antibodies in the plasma, and peripheral memory B-cells along with their associated antibody profiles elicited after in vitro stimulation. We found that magnitude varied amongst individuals, but was the highest in hospitalized subjects. Variants of concern (VoC) -RBD-reactive antibodies were found in the plasma of 72% of samples in this investigation, and VoC-RBD-reactive memory B-cells were found in all but 1 subject at a single time-point. This finding, that VoC-RBD-reactive MBCs are present in the peripheral blood of all subjects including those that experienced asymptomatic or mild disease, provides a reason for optimism regarding the capacity of vaccination, prior infection, and/or both, to limit disease severity and transmission of variants of concern as they continue to arise and circulate.

show abstract

“…These findings contrast with Faulkner et al who observed a decreased level of cross-neutralization in B.1.1.7 infected individuals. 38 However, Faulkner et al used sera collected at around 11 days POS and, as discussed above, cross-neutralizing activity likely develops over time. Here we show that, similar to wave 1 sera, neutralization of B.1.351 by B.1.1.7 sera was reduced compared neutralization of B.1.1.7 and suggests the shared N501Y mutation is not sufficient to overcome the B.1.351 neutralization resistance, an independent SARS-CoV-2 lineage.…”

Section: Discussionmentioning

confidence: 99%

Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections

Dupont

Snell

Graham

et al. 2021

Preprint

View full text Add to dashboard Cite

As SARS–CoV–2 variants continue to emerge globally, a major challenge for COVID–19 vaccination is the generation of a durable antibody response with cross–neutralizing activity against both current and newly emerging viral variants. Cross–neutralizing activity against major variants of concern (B.1.1.7, P.1 and B.1.351) has been observed following vaccination, albeit at a reduced potency, but whether vaccines based on the Spike glycoprotein of these viral variants will produce a superior cross–neutralizing antibody response has not been fully investigated. Here, we used sera from individuals infected in wave 1 in the UK to study the long-term cross-neutralization up to 10 months post onset of symptoms (POS), as well as sera from individuals infected with the B.1.1.7 variant to compare cross–neutralizing activity profiles. We show that neutralizing antibodies with cross-neutralizing activity can be detected from wave 1 up to 10 months POS. Although neutralization of B.1.1.7 and B.1.351 is lower, the difference in neutralization potency decreases at later timepoints suggesting continued antibody maturation and improved tolerance to Spike mutations. Interestingly, we found that B.1.1.7 infection also generates a cross-neutralizing antibody response, which, although still less potent against B.1.351, can neutralize parental wave 1 virus to a similar degree as B.1.1.7. These findings have implications for the optimization of vaccines that protect against newly emerging viral variants.

show abstract

Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains

Cited by 23 publications

References 16 publications

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals

SARS-CoV-2 specific memory B-cells from individuals with diverse disease severities recognize SARS-CoV-2 variants of concern

Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections

Contact Info

Product

Resources

About